{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-609.00","upperLimit":"1087.00","value":"-43.00"}]}],"title":"Month 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-435.00","upperLimit":"217.00","value":"0.00"}]}],"title":"Month 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-479.00","upperLimit":"913.00","value":"0.00"}]}],"title":"Month 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-653.00","upperLimit":"217.00","value":"0.00"}]}],"title":"Month 12"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Change in prolactin levels from baseline","dispersionType":"Full Range","groups":[{"description":"All patients randomized regardless of pasireotide LAR dose.","id":"OG000","title":"Pasireotide LAR - All Participants"}],"paramType":"MEDIAN","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. Protocol allowed to change treatment dose (eg, 20mg -\\> 40mg -\\>20mg -\\> 40mg -\\>60mg) based on efficacy and safety after 3month treatment. So we combined Arms/groups.","reportingStatus":"POSTED","timeFrame":"Baseline, Months 3, 6, 9, 12","title":"Change From Baseline in Prolactin","type":"SECONDARY","unitOfMeasure":"pmol/L"}